[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aron Research Foundation Ets\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100625301",false,"NCT07420855","International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la\u002FmUC","International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced\u002FMetastatic Urothelial Cancer (ARON-2PLUS)","ARON-2PLUS","Inclusion Criteria:\n\n* Patients aged \\>18years\n* Histologically confirmed diagnosis of la\u002FmUC of upper and\u002For lower urinary tract or histologically confirmed diagnosis of rare GU tumors.\n* Histologically or radiologically confirmed metastatic disease\n* Patients treated with first-line EV+P combination\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of UC\n* Patients without histologically or radiologically confirmed la or mUC","ALL","18 Years",{"count":19,"type":20},361,"ESTIMATED","OBSERVATIONAL","The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced\u002Fmetastatic Urothelial Cancer.\n\nTwo supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.",[24,25],"Locally Advanced or Metastatic Urothelial Cancer","Urothelial Cancer",[27,28,29,30],"urothelial cancer","pembrolizumab","enfortumab vedotin","rare genitourinary tumors","NOT_YET_RECRUITING","2026-02-12",{"date":34,"type":35},"2026-02-19","ACTUAL",{"date":37,"type":20},"2026-02",{"date":39,"type":20},"2030-12",{"name":41,"class":42},"Aron Research Foundation Ets","OTHER",""]